KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) Invested Capital (2016 - 2025)

Historic Invested Capital for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $18.3 billion.

  • Biogen's Invested Capital fell 1413.9% to $18.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $18.3 billion, marking a year-over-year decrease of 1413.9%. This contributed to the annual value of $18.3 billion for FY2025, which is 1413.9% down from last year.
  • According to the latest figures from Q4 2025, Biogen's Invested Capital is $18.3 billion, which was down 1413.9% from $24.5 billion recorded in Q3 2025.
  • Over the past 5 years, Biogen's Invested Capital peaked at $24.5 billion during Q3 2025, and registered a low of $17.2 billion during Q3 2021.
  • Moreover, its 5-year median value for Invested Capital was $20.4 billion (2023), whereas its average is $20.1 billion.
  • The largest annual percentage gain for Biogen's Invested Capital in the last 5 years was 1716.31% (2025), contrasted with its biggest fall of 1413.9% (2025).
  • Quarter analysis of 5 years shows Biogen's Invested Capital stood at $17.2 billion in 2021, then increased by 14.13% to $19.7 billion in 2022, then grew by 9.75% to $21.6 billion in 2023, then fell by 1.5% to $21.3 billion in 2024, then dropped by 14.14% to $18.3 billion in 2025.
  • Its last three reported values are $18.3 billion in Q4 2025, $24.5 billion for Q3 2025, and $23.9 billion during Q2 2025.